J. Leal

发表

ATM-dependent phosphorylation of Mdm2 on serine 395: role in p53 activation by DNA damage.

S. T. Kim, Y. Shiloh, M. Oren, 2001, Genes & development.

Regulation of p53: intricate loops and delicate balances.

M. Oren, Y. Taya, T. Gottlieb, 2002, Biochemical pharmacology.

Activation of phosphatidylinositol 3-kinase by membrane localization of p110alpha predisposes mammary glands to neoplastic transformation.

J. Leal, O. Renner, A. Carnero, 2008, Cancer research.

Inhibition of phosphatidylinositol-3-kinase synergizes with gemcitabine in low-passage tumor cell lines correlating with Bax translocation to the mitochondria

J. Leal, J. Velasco, A. Carnero, 2005, Anti-cancer drugs.

Molecular pharmacology and antitumor activity of Zalypsis in several human cancer cell lines.

Juan A. Bueren-Calabuig, J. Bueren-Calabuig, F. Gago, 2009, Biochemical pharmacology.

PM01183, a new DNA minor groove covalent binder with potent in vitro and in vivo anti‐tumour activity

Juan A. Bueren-Calabuig, J. Bueren-Calabuig, F. Gago, 2010, British journal of pharmacology.

MAP17 enhances the malignant behavior of tumor cells through ROS increase.

J. Leal, A. Carnero, J. Fominaya, 2007, Carcinogenesis.

MAP17 inhibits Myc-induced apoptosis through PI3K/AKT pathway activation.

J. Leal, W. Link, A. Carnero, 2007, Carcinogenesis.

Pim 1 kinase inhibitor ETP-45299 suppresses cellular proliferation and synergizes with PI3K inhibition.

J. Oyarzábal, J. Leal, J. Bischoff, 2011, Cancer letters.

Mst 1 , RanBP 2 and eIF 4 G are new markers for in vivo PI 3 K activation in murine and human prostate

J. Leal, O. Renner, A. Carnero, 2007 .

S-adenosylhomocysteine hydrolase downregulation contributes to tumorigenesis.

J. Leal, S. Y. Cajal, A. Carnero, 2008, Carcinogenesis.

Regulation of p53: intricate loops and delicate balances.

Moshe Oren, Alexander Damalas, Dan Michael, 2002, Biochemical pharmacology.

Levels of p27kip1 determine Aplidin sensitivity

J. Leal, A. Carnero, C. Blanco-Aparicio, 2007, Molecular Cancer Therapeutics.

The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications.

Wolfgang Link, Carmen Blanco-Aparicio, J. Leal, 2008, Current cancer drug targets.

PIM2 inhibition as a rational therapeutic approach in B-cell lymphoma.

J. Martinez-Climent, M. Piris, M. Sánchez-Beato, 2011, Blood.

PTEN, more than the AKT pathway.

Carmen Blanco-Aparicio, J. Leal, O. Renner, 2007, Carcinogenesis.

Excess β‐catenin promotes accumulation of transcriptionally active p53

B. Geiger, M. Oren, J. Leal, 1999, The EMBO journal.

Loss-of-function genetic screening identifies a cluster of ribosomal proteins regulating p53 function.

J. Leal, A. Carnero, S. Ramón y. Cajal, 2008, Carcinogenesis.

MAP17 overexpression is a common characteristic of carcinomas.

J. Leal, A. Carnero, J. Fominaya, 2007, Carcinogenesis.

Characterization of the p53 Response to Oncogene-Induced Senescence

J. Leal, A. Carnero, I. Ferrer, 2008, PloS one.

Cellular senescence bypass screen identifies new putative tumor suppressor genes

D. Beach, J. Leal, S. Y. Cajal, 2008, Oncogene.

PPP1CA contributes to the senescence program induced by oncogenic Ras.

J. Leal, A. Carnero, S. Ramón y. Cajal, 2007, Carcinogenesis.

Mst1, RanBP2 and eIF4G are new markers for in vivo PI3K activation in murine and human prostate.

J. Leal, O. Renner, A. Carnero, 2007, Carcinogenesis.

Mice expressing myrAKT1 in the mammary gland develop carcinogen-induced ER-positive mammary tumors that mimic human breast cancer.

J. Leal, O. Renner, A. Carnero, 2007, Carcinogenesis.

Regulation of p53

M. Oren, Y. Taya, T. Gottlieb, 2002, Annals of the New York Academy of Sciences.

Cross-talk between Akt, p53 and Mdm2: possible implications for the regulation of apoptosis

Moshe Oren, Rony Seger, Yoichi Taya, 2002, Oncogene.

Expression of XPG protein in human normal and tumor tissues.

Luis García Fernández, C. Galmarini, J. Leal, 2013, International journal of clinical and experimental pathology.

Physical and Functional Interaction between p53 and the Werner’s Syndrome Protein*

G. Schellenberg, G. Blander, Chang-En Yu, 1999, The Journal of Biological Chemistry.

Molecular pharmacology and antitumor activity of in several human cancer cell lines

J. Bueren-Calabuig, F. Gago, J. Leal, 2019 .

Extreme sensitivity to Yondelis® (Trabectedin, ET‐743) in low passaged sarcoma cell lines correlates with mutated p53

J. Cigudosa, M. Piris, M. Sánchez-Beato, 2007, Journal of cellular biochemistry.

In Vivo Transcription of nrdAB Operon and of grxA and fpg Genes Is Triggered inEscherichia coli Lacking both Thioredoxin and Glutaredoxin 1 or Thioredoxin and Glutathione, Respectively*

A. Holmgren, J. Leal, C. Pueyo, 1998, The Journal of Biological Chemistry.

Pim 1 kinase inhibitor ETP-45299 suppresses cellular proliferation and synergizes with PI3K inhibition.

J. Oyarzábal, J. Leal, J. Bischoff, 2011, Cancer letters.